Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.

Sasaoka T, Wada T, Tsuneki H.

Pharmacol Ther. 2006 Dec;112(3):799-809. Epub 2006 Jul 13. Review.

PMID:
16842857
2.
3.

Lipid phosphatases as drug discovery targets for type 2 diabetes.

Lazar DF, Saltiel AR.

Nat Rev Drug Discov. 2006 Apr;5(4):333-42. Review.

PMID:
16582877
4.

SHIP2: an emerging target for the treatment of type 2 diabetes mellitus.

Baumgartener JW.

Curr Drug Targets Immune Endocr Metabol Disord. 2003 Dec;3(4):291-8. Review.

PMID:
14683460
5.

The SH2 domain containing inositol polyphosphate 5-phosphatase-2: SHIP2.

Dyson JM, Kong AM, Wiradjaja F, Astle MV, Gurung R, Mitchell CA.

Int J Biochem Cell Biol. 2005 Nov;37(11):2260-5. Review.

PMID:
15964236
6.

The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease.

Ooms LM, Horan KA, Rahman P, Seaton G, Gurung R, Kethesparan DS, Mitchell CA.

Biochem J. 2009 Apr 1;419(1):29-49. doi: 10.1042/BJ20081673. Review.

PMID:
19272022
7.

SHIP2 multiple functions: a balance between a negative control of PtdIns(3,4,5)P₃ level, a positive control of PtdIns(3,4)P₂ production, and intrinsic docking properties.

Erneux C, Edimo WE, Deneubourg L, Pirson I.

J Cell Biochem. 2011 Sep;112(9):2203-9. doi: 10.1002/jcb.23146. Review.

PMID:
21503961
8.

Phosphoinositide phosphatases: just as important as the kinases.

Dyson JM, Fedele CG, Davies EM, Becanovic J, Mitchell CA.

Subcell Biochem. 2012;58:215-79. doi: 10.1007/978-94-007-3012-0_7. Review.

PMID:
22403078
9.

PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling.

Vinciguerra M, Foti M.

Arch Physiol Biochem. 2006 Apr;112(2):89-104. Review.

PMID:
16931451
10.
11.

SHIP2 and its involvement in various diseases.

Suwa A, Kurama T, Shimokawa T.

Expert Opin Ther Targets. 2010 Jul;14(7):727-37. doi: 10.1517/14728222.2010.492780. Review.

PMID:
20536411
12.

11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity.

Hughes KA, Webster SP, Walker BR.

Expert Opin Investig Drugs. 2008 Apr;17(4):481-96. doi: 10.1517/13543784.17.4.481 . Review.

PMID:
18363514
13.

Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.

Harley EA, Levens N.

Curr Opin Investig Drugs. 2003 Oct;4(10):1179-89. Review. Erratum in: Curr Opin Investig Drugs. 2003 Dec;4(12):1488.

PMID:
14649209
14.

Insulin resistance and improvements in signal transduction.

Musi N, Goodyear LJ.

Endocrine. 2006 Feb;29(1):73-80. Review.

PMID:
16622294
15.

Interdependence of hepatic lipid and glucose metabolism: novel pharmacological targets for diabetes.

Lind P.

Curr Opin Investig Drugs. 2004 Apr;5(4):395-401. Review.

PMID:
15134280
16.

Inhibition of protein tyrosine phosphatase 1B as a potential treatment of diabetes and obesity.

Pei Z, Liu G, Lubben TH, Szczepankiewicz BG.

Curr Pharm Des. 2004;10(28):3481-504. Review.

PMID:
15579047
17.

AMP-activated protein kinase in metabolic control and insulin signaling.

Towler MC, Hardie DG.

Circ Res. 2007 Feb 16;100(3):328-41. Review.

18.
19.

GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.

Overton HA, Fyfe MC, Reynet C.

Br J Pharmacol. 2008 Mar;153 Suppl 1:S76-81. Epub 2007 Nov 26. Review.

20.

Sirtuins as possible drug targets in type 2 diabetes.

Kitada M, Kume S, Kanasaki K, Takeda-Watanabe A, Koya D.

Curr Drug Targets. 2013 Jun 1;14(6):622-36. Review.

PMID:
23445543
Items per page

Supplemental Content

Write to the Help Desk